Showing results (81-90 of 96) with videos related to
Sort By:
Pageof 10
European Journal of Pharmacology|June 22, 2025
Comparative analysis of the antiglioblastoma activity of adenosine A2A receptor and CK1δ blockersAkshaya Murugesan, Anxo Vila Alonso, Saravanan Konda Mani, et al.Journal of Medicinal Chemistry|November 24, 2005
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferationWilma Quaglia, Giorgio Santoni, Maria Pigini, et al.Journal of Medicinal Chemistry|March 17, 2006
Highly chiral muscarinic ligands: the discovery of (2S,2'R,3'S,5'R)-1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide methyl iodide, a potent, functionally selective, M2 partial agonistSerena Scapecchi, Rosanna Matucci, Cristina Bellucci, et al.Journal of Medicinal Chemistry|November 26, 2009
Synthesis, affinity profile and functional activity of potent chiral muscarinic antagonists with a pyrrolidinylfuran structureSerena Scapecchi, Marta Nesi, Rosanna Matucci, et al.Biomolecules|July 29, 2025
Dissecting the tRNA Fragment tRF3E-Nucleolin Interaction: Implications in Breast CancerMaurizio Falconi, Junbiao Wang, Andrea Costamagna, et al.Journal of Medicinal Chemistry|August 28, 2019
Antioxidant-Conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic PainMatteo Falsini, Daniela Catarzi, Flavia Varano, et al.Molecules (Basel, Switzerland)|April 23, 2022
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?Andrea Spinaci, Catia Lambertucci, Michela Buccioni, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 12, 2026
Synthesis and characterization of new P2X7 receptor antagonists as antitumor agentsMarianna Grignolo, Andrea Spinaci, Ludovica Ricci, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 17, 2026
Unveiling the molecular crosstalk between the purinergic P2X7 receptor and cannabinoid subtype 2 receptor in human microglial HMC3 cells: New insights for multitarget therapies in neuroinflammationImane Ghafir El Idrissi, David Moreira Alvarez, Rocío Piña Márquez, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 12, 2025
A2A receptor antagonist 4-(2-((6-Amino-9-ethyl-8-(furan-2-yl)-9H-purin-2-yl)amino)ethyl)phenol, a promising adenosine derivative for glioblastoma treatmentAkshaya Murugesan, Aleksei Smirnov, Anxo Vila Alonso, et al.Pageof 10